Anokion has announced positive data from a completed Phase I trial investigating KAN-101 for coeliac disease treatment.
The trial (NCT04248855), termed ACeD, was a randomised, double-blind, placebo-controlled study that investigated 41 individuals with coeliac disease on a gluten-free diet across two cohorts of single-ascending dose and multi-ascending dose.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Early findings from the study demonstrated safety and tolerance of KAN-101, along with inducing functional tolerance of gliadin-specific T cells following gluten challenge. KAN-101 can specifically target parts of the immune system responsible for gluten immune reaction as opposed to conventional broad-sweeping immunosuppressants.
In the multi-ascending dose segment, patients were administered with KAN-101 on days 1,4, and 7 at dose levels of 0.15, 0.3, and 0.6 mg/kg or placebo. A three-day gluten challenge then followed on day 15.
The recent findings announced by the Swiss company demonstrated that KAN-101 was cleared from systemic circulation within approximately six hours in the multi-ascending cohort, and effects lasted up to three weeks after treatment. KAN-101 also increased gliadin-specific, tetramer+ T cells and, after the gluten challenge, led to a dose-dependent modulation of interleukin-2.
The company plans to continue with Phase II initiation in 2023, with initial data expected in early 2024.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataCoeliac disease is an autoimmune condition that affects around 2 million people in the US, according to the National Institutes of Health. Whilst there is no cure, current treatments explore suppressing immune reactions, managing symptoms, and alleviating long-term health effects. “As a highly burdensome condition with no disease-modifying therapies available today, KAN-101 could be a game changer for patients, with durable treatment effects observed following administration,” said Deborah Geraghty, Ph.D., chief executive officer of Anokion.
